Slingshot members are tracking this event:

Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details  Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed the enrollment and dosing of patients in its ongoing Phase 1b trial evaluating its investigational new drug, PEGPH20, in combination with KEYTRUDA (pembrolizumab) in patients with advanced non-small cell lung and gastric cancers under a revised clinical protocol. The revised protocol has been submitted to all institutional review boards (IRB) and is pending feedback from the FDA. The majority of IRBs have completed their review and approved the revised protocol allowing the study to resume. 
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 25, 2016
Related Projects Image
Related Keywords Pegph20, Keytruda, Pembrolizumab, Gastric Cancers, Nsclc